Ask AI
ProCE Banner Activity

Promesse, insidie e percorsi: prospettive globali sui biomarcatori ematici per la cura dell’Alzheimer

Clinical Thought

Esperti della malattia di Alzheimer provenienti da tutto il mondo offrono le loro riflessioni sui biomarcatori ematici, inclusa la loro iniziale adozione nella pratica clinica in diverse parti del mondo e il loro potenziale inserimento futuro nei percorsi diagnostici dei sistemi sanitari.

Released: June 05, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global primary care physicians, general practitioners, general neurologists, nurse practitioners, physician associates, and other healthcare professionals caring for patients at risk of developing Alzheimer’s Disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Applicare strategie basate sull’evidenza e linee guida cliniche sui test dei biomarcatori per orientare il processo decisionale clinico e gli invii agli specialisti lungo l’intero percorso di cura dell’AD

Disclosure

Primary Author

Atsushi Iwata, MD, PhD: consultant/advisor/speaker: Biogen, Eisai, Fujirebio, Janssen, Kowa, Lilly, MSD, Otsuka, Sony, Sysmex, UCB.

Sebastian Palmqvist, MD, PhD: consultant/advisor/speaker: BioArctic, Danaher, Eisai, Lilly, Novo Nordisk, Roche, Sanofi.

Jiong Shi, MD, PhD, FAAN, has no relevant financial relationships to disclose.

Raymond Scott Turner, PhD, MD, FANA, FAAN: researcher (paid to institution): Cognition Therapeutics, Eisai, Lilly; consultant/advisor/speaker: Lilly.